Aldeyra Therapeutics (ALDX) Gets a Buy Rating from H.C. Wainwright
H.C. Wainwright analyst Edwin Zhang reiterated a Buy rating on Aldeyra Therapeutics (ALDX) today and set a price target of $26.00. The company’s shares closed last Monday at $12.85.
According to TipRanks.com, Zhang is a 1-star analyst with an average return of -10.9% and a 44.4% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Calliditas Therapeutics, Liminal BioSciences, and FibroGen.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aldeyra Therapeutics with a $25.50 average price target, which is a 103.0% upside from current levels. In a report issued on April 21, Leerink Partners also maintained a Buy rating on the stock with a $22.00 price target.
See today’s analyst top recommended stocks >>
Based on Aldeyra Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $11.29 million. In comparison, last year the company had a GAAP net loss of $13.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.